Another ANDA bolus is coming, although not because of a new US FDA policy or assessment time change.
If generic drug sponsors adhere to historical averages, the total number of applications processed upon the end of the government...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?